US stock · Healthcare sector · Medical Devices
Company Logo

Edwards Lifesciences Corporation

EWNYSE

86.48

USD
-0.96
(-1.10%)
Market Closed
37.28P/E
32Forward P/E
2.06P/E to S&P500
53.613BMarket CAP
- -Div Yield
Upcoming Earnings
25 Oct-31 Oct
Shares Short
9/15/22
6.54M
Short % of Float
1.06%
Short % of Shares Outs.
1.06%
% Held by Insiders
0.81%
% Held by Institutions
84.70%
Beta
1.14
PEG Ratio
2.73
52w. high/low
131.73/81.87
Avg. Daily Volume
2.56M
Return %
Stock
S&P 500
1 year
(22.52)
(15.03)
3 years
15.00
27.03
5 years
132.47
47.04
Scale: |
High
Low
4.41
3.80
5.58
3.47
7.35
4.41
14.24
7.05
15.30
10.27
18.46
11.31
15.83
10.10
22.38
10.51
27.81
20.46
40.58
24.07
40.48
28.85
58.33
36.89
82.55
46.95
92.08
51.51
131.73
78.44
131.09
81.87
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
1.48
1.59
1.85
1.96
2.12
2.44
2.76
3.05
3.64
3.86
4.64
5.43
5.93
6.96
7.05
8.39
8.60
Earnings per share
0.19
0.16
0.19
0.34
0.32
0.34
0.43
0.58
1.27
0.77
0.89
0.92
1.15
1.68
1.32
2.41
2.34
FCF per share
0.24
0.21
0.11
0.15
0.28
0.33
0.36
0.54
1.45
0.69
0.76
1.30
1.09
1.44
1.04
2.25
2.02
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.08
0.09
0.12
0.09
0.09
0.13
0.19
0.16
0.15
0.16
0.34
0.28
0.39
0.45
0.65
0.53
0.43
Book Value per sh.
1.07
1.21
1.31
1.71
1.92
1.95
2.15
2.33
3.43
3.87
4.10
4.67
5.00
6.64
7.35
9.36
9.30
Comm.Shares outs.
702
688
670
676
682
688
689
670
639
647
639
633
628
625
623
624
623
Avg. annual P/E ratio
20.0
24.9
23.1
16.3
29.3
38.2
34.6
21.1
12.1
30.9
36.5
38.9
41.3
39.6
57.0
42.3
37.3
P/E to S&P500
1.1
1.4
1.1
0.2
1.4
2.3
2.3
1.2
0.7
1.5
1.6
1.6
1.7
1.6
1.5
1.4
2.1
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
1,037
1,091
1,238
1,321
1,447
1,679
1,900
2,046
2,323
2,494
2,964
3,435
3,723
4,348
4,386
5,233
5,355
Operating margin
16.7%
15.8%
16.0%
18.0%
19.6%
17.9%
21.5%
22.2%
20.8%
25.8%
26.4%
29.8%
20.1%
26.4%
20.5%
32.3%
31.0%
Depreciation (m)
57
55
56
59
57
58
57
69
69
66
71
82
77
89
107
135
135
Net profit (m)
131
113
129
229
218
237
293
392
811
495
570
584
722
1,047
823
1,503
1,455
Income tax rate
24.3%
24.6%
21.6%
24.7%
18.7%
16.5%
25.0%
24.0%
29.1%
20.5%
22.8%
43.6%
5.1%
10.3%
10.2%
11.7%
12.7%
Net profit margin
12.6%
10.4%
10.4%
17.3%
15.1%
14.1%
15.4%
19.1%
34.9%
19.8%
19.2%
17.0%
19.4%
24.1%
18.8%
28.7%
27.2%
Working capital (m)
305
206
433
599
695
833
945
1,380
1,860
1,572
1,708
1,129
1,410
2,082
2,197
2,148
2,294
Long-term debt (m)
236
62
176
90
- -
150
189
593
598
600
822
438
594
594
668
665
660
Equity (m)
749
835
879
1,158
1,308
1,338
1,479
1,559
2,191
2,503
2,619
2,956
3,140
4,148
4,574
5,836
5,944
ROIC
12.8%
11.7%
11.8%
17.4%
15.4%
14.5%
15.8%
16.8%
26.6%
14.2%
14.7%
13.9%
16.9%
19.1%
13.2%
20.3%
19.6%
Return on capital
13.8%
11.1%
12.3%
19.0%
15.3%
14.5%
17.8%
19.3%
32.9%
15.8%
16.8%
18.6%
14.9%
18.3%
12.9%
20.2%
19.8%
Return on equity
17.4%
13.5%
14.7%
19.8%
16.7%
17.7%
19.8%
25.1%
37.0%
19.8%
21.7%
19.7%
23.0%
25.2%
18.0%
25.8%
24.5%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
65.6%
62.4%
322.7%
28.4%
57.3%
108.9%
99.1%
124.5%
20.2%
43.5%
114.8%
78.7%
94.7%
11.4%
96.7%
36.6%
68.1%
Capital Structure
29 Jul · 2022 | Q2
All numbers in millions
Total liabilities
$ 2,482
Total assets
$ 8,425
Long-term debt
$ 660
Cash and equiv.
$ 1,198
Goodwill
$ 1,164
Retained earnings
$ 6,848
Common stock
621
Enterprise Value
$ 53,074
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
1,517
1,403
1,467
Receivables
599
603
665
Inventory
641
802
727
Other
227
287
6
Current assets
2,984
3,091
3,181
Acc. Payable
180
197
205
Debt due
26
27
26
Other
697
670
802
Current liabilities
902
894
1,032
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
19.29%
11.33%
12.08%
Cash flow
116.74%
25.77%
37.06%
Earnings
82.55%
32.48%
27.68%
Dividends
- -
- -
- -
Book value
27.58%
19.04%
17.09%
Insider Trading
Type
Shares
Date
Mussallem Michael A
Exempt
29,375
09/22/22
Mussallem Michael A
Gift
9,500
09/22/22
Mussallem Michael A
Sale
16,675
09/22/22
Mussallem Michael A
Gift
9,500
09/22/22
Mussallem Michael A
Sale
3,100
09/22/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
1,129
925
1,141
1,192
4,386
2021
1,217
1,376
1,310
1,330
5,233
2022
1,341
1,374
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.50
(0.20)
0.52
0.50
1.32
2021
0.54
0.78
0.55
0.54
2.41
2022
0.60
0.65
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Michael Mussallem
Full-time employees:
15,700
City:
Irvine
Address:
1 Edwards Way
IPO:
Mar 27, 2000
Website:
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Recent News